Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.400
+0.020 (1.45%)
Aug 28, 2026, 3:12 PM EDT - Market open
Allarity Therapeutics Revenue
Allarity Therapeutics had revenue of $345.00K in the twelve months ending June 30, 2026. In the year 2025, Allarity Therapeutics had annual revenue of $320.00K.
Revenue (ttm)
$345.00K
Revenue Growth
n/a
P/S Ratio
63.64
Revenue / Employee
$43,125
Employees
8
Market Cap
22.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 320.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cerenome | 4.20M |
| Dyadic International | 3.80M |
| Longeveron | 1.19M |
| Cocrystal Pharma | 330.00K |
| Neuphoria Therapeutics | -13.27K |
ALLR News
- 14 days ago - Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewsWire
- 2 months ago - Allarity to present trial-in-progress poster on Phase 2 stenoparib trial - TheFly
- 2 months ago - Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 4 months ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 4 months ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire